

Lucy Abraham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7970355/publications.pdf>

Version: 2024-02-01

24
papers

861
citations

933264

10
h-index

610775

24
g-index

24
all docs

24
docs citations

24
times ranked

898
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of osteoarthritis disease severity on treatment patterns and healthcare resource use: analysis of real-world data. <i>Scandinavian Journal of Rheumatology</i> , 2023, 52, 353-363.	0.6	2
2	Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. <i>European Journal of Pain</i> , 2022, 26, 648-667.	1.4	7
3	An Observational Retrospective Matched Cohort Study of Healthcare Resource Utilisation and Costs in UK Patients with Moderate to Severe Osteoarthritis Pain. <i>Rheumatology and Therapy</i> , 2022, 9, 851-874.	1.1	3
4	WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. <i>Journal of Rheumatology</i> , 2022, 49, 615-621.	1.0	8
5	Time to first and sustained improvement in WOMAC domains among patients with osteoarthritis receiving tanezumab. <i>Osteoarthritis and Cartilage Open</i> , 2022, 4, 100294.	0.9	1
6	Are pain severity and current pharmacotherapies associated with quality of life, work productivity, and healthcare utilisation for people with osteoarthritis in five large European countries?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 819-828.	0.4	4
7	Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 1202-1213.	0.6	31
8	FRI0397&€...THE IMPACT OF OSTEOARTHRITIS DISEASE SEVERITY ON HEALTHCARE RESOURCE USE: ANALYSIS OF REAL-WORLD EUROPEAN DATA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 796.3-797.	0.5	1
9	<p>A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: Chinese perspective</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 169-177.	0.7	7
10	Psychometric evaluation of electronic diaries assessing side-effects of hormone therapy. <i>Climacteric</i> , 2018, 21, 594-600.	1.1	2
11	Evaluation of a crosswalk between the European Quality of Life Five Dimension Five Level and the Menopause-Specific Quality of Life questionnaire. <i>Climacteric</i> , 2018, 21, 566-573.	1.1	2
12	Time to first occurrence of breast pain and vaginal bleeding in phase 3 trials of CE/BZA. <i>Menopause</i> , 2017, 24, 1372-1377.	0.8	2
13	Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning. <i>Maturitas</i> , 2017, 100, 57-63.	1.0	30
14	Direct and indirect effects of conjugated estrogens/bazedoxifene treatment on quality of life in postmenopausal women. <i>Maturitas</i> , 2016, 94, 173-179.	1.0	6
15	Qualitative cross-cultural exploration of breast symptoms and impacts associated with hormonal treatments for menopausal symptoms to inform the development of new patient-reported measurement tools. <i>Maturitas</i> , 2015, 80, 273-281.	1.0	8
16	Evaluation of the Efficacy and Safety of Bazedoxifene/Conjugated Estrogens for Secondary Outcomes Including Vasomotor Symptoms in Postmenopausal Women by Years Since Menopause in the Selective Estrogens, Menopause and Response to Therapy (SMART) Trials. <i>Journal of Women's Health</i> , 2014, 23, 18-28.	1.5	46
17	Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens. <i>Menopause</i> , 2014, 21, 252-259.	0.8	44
18	Qualitative cross-cultural exploration of vaginal bleeding/spotting symptoms and impacts associated with hormone therapy in post-menopausal women to inform the development of new patient-reported measurement tools. <i>Maturitas</i> , 2014, 78, 219-227.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene. <i>Maturitas</i> , 2014, 78, 212-218.	1.0	17
20	Confirmatory Factor Analysis and Evaluation of Clinically Important Differences in Menopause-Specific Quality of Life Associated with Bazedoxifene/Conjugated Estrogens in a Vulvar/Vaginal Atrophy Population. <i>Value in Health</i> , 2013, 16, A337.	0.1	1
21	Psychometric Validation of Gender Nonspecific Sexual Confidence and Sexual Relationship Scales in Men and Women. <i>Journal of Sexual Medicine</i> , 2009, 6, 2244-2254.	0.3	21
22	Psychometric Validation of a Sexual Quality of Life Questionnaire for Use in Men with Premature Ejaculation or Erectile Dysfunction. <i>Journal of Sexual Medicine</i> , 2008, 5, 595-601.	0.3	116
23	Development and Validation of a Premature Ejaculation Diagnostic Tool. <i>European Urology</i> , 2007, 52, 565-573.	0.9	337
24	Development and Validation of a New Questionnaire to Assess Sexual Satisfaction, Control, and Distress Associated with Premature Ejaculation. <i>Journal of Sexual Medicine</i> , 2006, 3, 465-475.	0.3	153